Refine
Is part of the Bibliography
- yes (33)
Year of publication
Document Type
- Journal article (33) (remove)
Language
- English (33)
Keywords
- apoptosis (8)
- cell death (6)
- TNF (5)
- TNFR2 (5)
- Fn14 (4)
- NFκB (4)
- TNF receptor superfamily (4)
- TWEAK (4)
- TNFR1 (3)
- TRAF2 (3)
- antibody (3)
- cytokines (3)
- death receptors (3)
- inflammation (3)
- necroptosis (3)
- CD40 (2)
- CD40L (2)
- FcγR (2)
- TNF superfamily (2)
- TRAIL (2)
- Tumor-necrosis-factor (2)
- agonistic antibodies (2)
- antibody fusion proteins (2)
- cancer therapy (2)
- caspase-8 (2)
- immunotherapy (2)
- multiple myeloma (2)
- necrotic cell death (2)
- regulatory T cells (2)
- tumor necrosis factor (TNF) (2)
- 14.7K (1)
- AMPK (1)
- Activation (1)
- Alpha therapy (1)
- Alpha-dependent apoptosis (1)
- Apoptosis (1)
- Autoimmune diseases (1)
- B cells (1)
- B-cell lymphoma (1)
- Bioluminescence (1)
- Bone marrow transplantantation (1)
- C-IAP1 (1)
- C1q/TNF related protein (CTRP) (1)
- CD20 (1)
- CD95 (1)
- CIAP1 (1)
- Callyspongia siphonella (1)
- Cancer (1)
- Caspase-8 activation (1)
- Complex (1)
- CysLTR1 (1)
- Cysteine‐Rich Domain (CRD) (1)
- Dopamine (1)
- E3 14.7-kilodalton protein (1)
- EpCAM (1)
- Expression (1)
- Factor receptor (1)
- FcγR receptor (1)
- GVHD (1)
- Gaussia princeps luciferase (GpL) (1)
- Glutamate-induced excitotoxicity (1)
- Graft-versus-leukemia (1)
- GvHD (1)
- HT29 cells (1)
- Kappa-B activation (1)
- Kappa-B pathway (1)
- LC-HRESIMS (1)
- Ligand (1)
- MDSC (1)
- Medizin (1)
- NF-kappa-B (1)
- NFkappaB (1)
- Necrosis (1)
- Parkinsons-disease (1)
- Pre‐Ligand Assembly Domain (PLAD) (1)
- RAF1 (1)
- RIP1 (1)
- Regulatory-cells (1)
- Rheumatoid arthritis (1)
- ScFv (1)
- Signaling complex (1)
- Single-chain TNF (1)
- Single‐Molecule Localization Microscopy (SMLM) (1)
- Suppression (1)
- T cells (1)
- T-cells (1)
- TNF ligand superfamily (1)
- TNF receptor (TNFR) family (1)
- TNF receptor 2 (TNFR2) (1)
- TNF receptor associated factor 1 and 2 (TRAF1, TRAF2) (1)
- TNF receptor associated factor 2 (TRAF2) (1)
- TNFR family costimulatory receptors (1)
- TNFR2 agonists (1)
- TNFR2 antagonism (1)
- TRAF1 (1)
- TRAILR1 (1)
- TRAILR2 (1)
- Tregs (regulatory T cells) (1)
- adiponectin (1)
- affinity (1)
- agonism (1)
- agonist (1)
- anti-TNFRSF receptor (TNFR) antibodies (1)
- antibacterial (1)
- antibiofilm (1)
- antibody fusion protein (1)
- anticancer (1)
- antitrypanosomal (1)
- autologous tumor (1)
- autophagy (1)
- binding (1)
- cancer (1)
- cancer treatment (1)
- cell cycle and cell division (1)
- cell metabolism (1)
- cell staining (1)
- cell viability testing (1)
- cells (1)
- cellular inhibitor of apoptosis 1/2 (cIAP1/2) (1)
- compartmentalization (1)
- costimulation (1)
- cytokine storm (1)
- dendritic cells (1)
- drug-delivery (1)
- extracellular matrix (1)
- gene expression (1)
- graft vs. host disease (1)
- heart (1)
- immune cells (1)
- immune modulation (1)
- immune regulation (1)
- inhibitor (1)
- metabolism (1)
- metabolomic profiling (1)
- metastasis (1)
- molecular medicine (1)
- monoclonal-antibodies (1)
- myocardial infarction (1)
- myocardium (1)
- myosin-VI (1)
- nanoparticles (1)
- neutrophils (1)
- nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NFκB) (1)
- oxindole alkaloids (1)
- phosphorylation (1)
- receptor cluster (1)
- regulatory T cell (1)
- regulatory T-cell (Treg) (1)
- ripk1 (1)
- ripk3 (1)
- serum retention (1)
- signal inhibition (1)
- signal transduction (1)
- small interfering RNAs (1)
- surface modification (1)
- targeting (1)
- tisindoline (1)
- tumor necrosis factor (1)
Institute
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (24)
- Medizinische Klinik und Poliklinik II (13)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (3)
- Julius-von-Sachs-Institut für Biowissenschaften (2)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (2)
- Medizinische Klinik und Poliklinik I (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Graduate School of Life Sciences (1)
- Institut für Pharmakologie und Toxikologie (1)
- Institut für Virologie und Immunbiologie (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 813871 (4)
Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity
(2023)
Fibroblast growth factor (FGF)-inducible 14 (Fn14) activates the classical and alternative NFκB (nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells) signaling pathway but also enhances tumor necrosis factor (TNF)-induced cell death. Fn14 expression is upregulated in non-hematopoietic cells during tissue injury and is also often highly expressed in solid cancers. In view of the latter, there were and are considerable preclinical efforts to target Fn14 for tumor therapy, either by exploiting Fn14 as a target for antibodies with cytotoxic activity (e.g. antibody-dependent cellular cytotoxicity (ADCC)-inducing IgG variants, antibody drug conjugates) or by blocking antibodies with the aim to interfere with protumoral Fn14 activities. Noteworthy, there are yet no attempts to target Fn14 with agonistic Fc effector function silenced antibodies to unleash the proinflammatory and cell death-enhancing activities of this receptor for tumor therapy. This is certainly not at least due to the fact that anti-Fn14 antibodies only act as effective agonists when they are presented bound to Fcγ receptors (FcγR). Thus, there are so far no antibodies that robustly and selectively engage Fn14 signaling without triggering unwanted FcγR-mediated activities. In this study, we investigated a panel of variants of the anti-Fn14 antibody 18D1 of different valencies and domain architectures with respect to their inherent FcγR-independent ability to trigger Fn14-associated signaling pathways. In contrast to conventional 18D1, the majority of 18D1 antibody variants with four or more Fn14 binding sites displayed a strong ability to trigger the alternative NFκB pathway and to enhance TNF-induced cell death and therefore resemble in their activity soluble (TNF)-like weak inducer of apoptosis (TWEAK), one form of the natural occurring ligand of Fn14. Noteworthy, activation of the classical NFκB pathway, which naturally is predominately triggered by membrane-bound TWEAK but not soluble TWEAK, was preferentially observed with a subset of constructs containing Fn14 binding sites at opposing sites of the IgG scaffold, e.g. IgG1-scFv fusion proteins. A superior ability of IgG1-scFv fusion proteins to trigger classical NFκB signaling was also observed with the anti-Fn14 antibody PDL192 suggesting that we identified generic structures for Fn14 antibody variants mimicking soluble and membrane-bound TWEAK.